Perspective Therapeutics, Inc.
CATXAMEXHealthcare● Active
$2.93
$-0.10(-3.30%)
Market Cap$226342500
P/E Ratio—
52W High$6.16
52W Low$1.96
Perspective Therapeutics, Inc. (CATX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CATX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2022-06 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.01B | $0.01B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.01B | $0.01B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | 100.00% | 23.00% | 42.76% |
| Operating Expenses | |||||
| R&D Expenses | $0.08B | $0.04B | $0.02B | $0.00B | $0.00B |
| G&A Expenses | $0.03B | $0.03B | $0.02B | $0.01B | $0.01B |
| Total Operating Expenses | $0.11B | $0.09B | $0.04B | $0.02B | $0.01B |
| Operating Income | ($0.11B) | $0.01B | ($0.04B) | ($0.02B) | ($0.01B) |
| Operating Margin %(computed) | — | — | — | -213.71% | -68.47% |
| Interest Income | $0.01B | $0.01B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | ($0.00B) | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.10B) | ($0.08B) | ($0.04B) | ($0.01B) | ($0.01B) |
| Income Tax Expense | ($0.00B) | ($0.00B) | ($0.00B) | $0.00B | ($0.00B) |
| Net Income | ($0.10B) | ($0.08B) | ($0.05B) | ($0.01B) | ($0.01B) |
| Net Margin %(computed) | — | — | — | -206.50% | -66.26% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.40 | $-1.23 | $-0.85 | $-0.27 | $-0.13 |
| Wtd Avg Shares | 0.07B | 0.06B | 0.05B | 0.05B | 0.05B |
| EBITDA | ($0.10B) | $0.01B | ($0.04B) | ($0.01B) | ($0.01B) |
| EBITDA Margin %(computed) | — | — | — | -208.87% | -68.47% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Perspective Therapeutics, Inc. data
About Perspective Therapeutics, Inc. (CATX) Income Statement
Perspective Therapeutics, Inc. (CATX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CATX reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.10B) — a net profit margin of —.
Frequently asked questions
CATX · 4 questionsPerspective Therapeutics, Inc. (CATX) reported revenue of $0.00B for 2025, down —% year-over-year.
CATX revenueCATX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08